CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma

Sorafenib is the first-line drug used for patients with advanced hepatocellular carcinoma (HCC). However, acquired sorafenib resistance in cancer patients limits its efficacy. Here, we performed the first genome-wide CRISPR/Cas9-based screening on sorafenib-treated HCC cells to identify essential ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Adi, Chevalier, Nadja, Calderoni, Margot, Dubuis, Gilles, Dormond, Olivier, Ziros, Panos G., Sykiotis, Gerasimos P., Widmann, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925031/
https://www.ncbi.nlm.nih.gov/pubmed/31903165
http://dx.doi.org/10.18632/oncotarget.27361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925031/
https://www.ncbi.nlm.nih.gov/pubmed/31903165
http://dx.doi.org/10.18632/oncotarget.27361

Ejemplares similares